Log in

NASDAQ:PTGXProtagonist Therapeutics Stock Price, Forecast & News

$16.22
+0.72 (+4.65 %)
(As of 06/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$15.28
Now: $16.22
$16.62
50-Day Range
$6.51
MA: $11.79
$17.05
52-Week Range
$4.47
Now: $16.22
$17.84
Volume715,217 shs
Average Volume644,286 shs
Market Capitalization$445.00 million
P/E RatioN/A
Dividend YieldN/A
Beta1.4
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD. It is also involved in researching oral and injectable peptide-based product candidates for a range of conditions, including gastrointestinal diseases. The company was founded in 2006 and is headquartered in Newark, California.
Read More
Protagonist Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.07 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTGX
CUSIPN/A
Phone510-474-0170

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$230,000.00
Book Value$2.94 per share

Profitability

Net Income$-77,190,000.00

Miscellaneous

Employees64
Market Cap$445.00 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive PTGX News and Ratings via Email

Sign-up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter.

Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions

How has Protagonist Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Protagonist Therapeutics' stock was trading at $7.16 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PTGX shares have increased by 126.5% and is now trading at $16.22. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Protagonist Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Protagonist Therapeutics.

When is Protagonist Therapeutics' next earnings date?

Protagonist Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Protagonist Therapeutics.

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics Inc (NASDAQ:PTGX) issued its earnings results on Thursday, May, 7th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by $0.03. The business had revenue of $3.65 million for the quarter, compared to the consensus estimate of $3.60 million. View Protagonist Therapeutics' earnings history.

What price target have analysts set for PTGX?

5 brokers have issued 1-year price targets for Protagonist Therapeutics' stock. Their forecasts range from $28.00 to $33.00. On average, they anticipate Protagonist Therapeutics' stock price to reach $30.60 in the next twelve months. This suggests a possible upside of 88.7% from the stock's current price. View analysts' price targets for Protagonist Therapeutics.

Has Protagonist Therapeutics been receiving favorable news coverage?

News stories about PTGX stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Protagonist Therapeutics earned a news impact score of -2.7 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutProtagonist Therapeutics.

Are investors shorting Protagonist Therapeutics?

Protagonist Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 1,120,000 shares, a decrease of 13.8% from the April 30th total of 1,300,000 shares. Based on an average trading volume of 760,700 shares, the short-interest ratio is currently 1.5 days. Approximately 5.4% of the company's stock are sold short. View Protagonist Therapeutics' Current Options Chain.

Who are some of Protagonist Therapeutics' key competitors?

What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include Viking Therapeutics (VKTX), Agile Therapeutics (AGRX), TG Therapeutics (TGTX), ImmunoGen (IMGN), Novavax (NVAX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Abeona Therapeutics (ABEO) and Energy Transfer LP Unit (ET).

Who are Protagonist Therapeutics' key executives?

Protagonist Therapeutics' management team includes the following people:
  • Dr. Dinesh V. Patel, CEO, Pres, Interim Principal Financial Officer, Interim PAO, Sec. & Director (Age 62)
  • Dr. Richard S. Shames, Chief Medical Officer (Age 59)
  • Dr. David Y. Liu, Chief Scientific Officer and Head of R&D (Age 69)
  • Dr. Mark Smythe, VP of Technology (Age 54)
  • Dr. Samuel R. Saks, Chief Devel. Officer (Age 64)

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.

What is Protagonist Therapeutics' stock symbol?

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (5.68%), JPMorgan Chase & Co. (3.22%), Sphera Funds Management LTD. (1.92%), State Street Corp (1.16%), Geode Capital Management LLC (1.07%) and Ghost Tree Capital LLC (0.83%). Company insiders that own Protagonist Therapeutics stock include Bryan Giraudo, David Y Liu, Dinesh V Ph D Patel, Donald A Kalkofen, Harold E Selick, Richard S Shames and Suneel Gupta. View institutional ownership trends for Protagonist Therapeutics.

Which major investors are selling Protagonist Therapeutics stock?

PTGX stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Sphera Funds Management LTD., Nuveen Asset Management LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Squarepoint Ops LLC, WINTON GROUP Ltd, and Ghost Tree Capital LLC. Company insiders that have sold Protagonist Therapeutics company stock in the last year include David Y Liu, and Dinesh V Ph D Patel. View insider buying and selling activity for Protagonist Therapeutics.

Which major investors are buying Protagonist Therapeutics stock?

PTGX stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., VR Adviser LLC, Invesco Ltd., Ikarian Capital LLC, Russell Investments Group Ltd., UBS Group AG, Los Angeles Capital Management & Equity Research Inc., and Geode Capital Management LLC. Company insiders that have bought Protagonist Therapeutics stock in the last two years include Bryan Giraudo, Donald A Kalkofen, Harold E Selick, and Suneel Gupta. View insider buying and selling activity for Protagonist Therapeutics.

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Protagonist Therapeutics' stock price today?

One share of PTGX stock can currently be purchased for approximately $16.22.

How big of a company is Protagonist Therapeutics?

Protagonist Therapeutics has a market capitalization of $445.00 million and generates $230,000.00 in revenue each year. The company earns $-77,190,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis. Protagonist Therapeutics employs 64 workers across the globe.

What is Protagonist Therapeutics' official website?

The official website for Protagonist Therapeutics is www.protagonist-inc.com.

How can I contact Protagonist Therapeutics?

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The company can be reached via phone at 510-474-0170 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.